NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t be recommended for use in the NHS because at its current price, it doesn’t have the potential to be cost-effective.
-
Make use of community pharmacists’ skills, says NICE
Community pharmacy teams have the potential to play a greater role in health promotion and prevention says NICE, in a new draft quality standard.
-
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
-
Implantable cardiac monitors detect atrial fibrillation after stroke of unknown cause recommended for routine NHS adoption
Doctors can check on their patients remotely using Reveal LINQ monitor
